

Medigenomix Receives Award for the Establishment of Relevant SNPs According to Gene Diagnostic and Pharmacogenetic

Brussels/ Munich, July 21, 2004

Medigenomix GmbH, a subsidiary of the Eurofins Group based in Munich/Germany, received an award of about € 1 mio. from the German Federal Ministry of Education and Research within the framework of the "BioChance Plus" competition. The ministry thereby supports application-oriented high-risk research and development projects of small and medium-sized biotechnology enterprises. This programme aims at accelerating technology transfer from basic research and the formulation of market utilisation strategies. The successful proposal is one of only a few of about 220 submitted project drafts that have been chosen due to its individualised medicine concept. The proposal includes the establishment of innovative, ready-for-market, all-purpose DNA-tests for individual gene diagnostics to predict the course of disorders and the individual response to drug therapies. In cooperation with the University Hospital Essen polymorphisms in genes (SNPs) coding for G-proteins will be screened and validated. As G-proteins play a pivotal role in signal transduction processes from receptors to intracellular components in all human tissues, variations in their protein structure or expression influence all drug actions and the natural courses of common disorders.

With this project, Medigenomix expands its efforts and research capacities in the field of Pharmacogenetics by a further research area. Hitherto, Medigenomix, located in Martinsried near Munich, offered analytical and pharmacogenetic consulting service for clinical trials in the biopharmaceutical industry using the acquired exclusive licenses of polymorphisms in G-proteins. With the support of the BioChance Plus Programme, the company is now able to carry out its own research in the field of pharmacogenetics in cooperation with Prof. Siffert's group at the University Hospital Essen and will thus strengthen its competence in G-protein-polymorphisms. The technological and scientific know-how of both partners will be bundled and the validated diagnostic tests will be submitted for international patent applications. Thereby, Medigenomix will make an important contribution to individualised medicine.

Medigenomix is a renowned service laboratory for DNA analyses with longstanding experience in genotyping for a broad range of applications from breeding to forensics and medicine.

For further information please visit www.medigenomix.com or contact:

- **Technical & commercial inquiries**

Dr. Brigitte Obermaier
Dr. Engelbert Precht
(Managing Directors, Medigenomix)
Phone: +49-89-89 98 92-0
Email: precht@medigenomix.de

- **Investor Relations**

Dr. Stefan Eckhoff
(International Investor Relations)
Phone: +32-2-766 16 20
E-mail: ir@eurofins.com

Hugues Vaussy
(Investor Relations France)
Phone: +33-2-51 83 21 00
E-mail: irFrance@eurofins.com

Company Profile Eurofins Group:

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of bioanalytical support services drawing on the latest developments in biotechnology. The Group specialises in delivering analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors. The Eurofins Group aims to become a world market leader in this field of applied life sciences and is pursuing a dynamic expansion strategy to improve both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field to offer its clients unparalleled analytical solutions.

With over 2,000 staff in more than 40 laboratories across 12 countries and a portfolio of around 5,000 analytical methods for proving the authenticity, origin, safety, identity, and purity of biological substances, Eurofins Scientific is already a leading global provider of bioanalytical services. The Group is committed to supporting its clients' objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate. Eurofins Scientific intends to continue to develop, acquire or license the most comprehensive range of state-of-the-art analytical technologies in order to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on Euronext in Paris (ISIN FR0000038259) and on the Frankfurt (WKN 910251) Stock Exchange (Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).

Important disclaimer:

This press release might contain forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements.